Back

TSPAN1 promotes human pancreatic cancer cells proliferation by modulating CDK1 via Akt

shi, g.; WANG, X.; GAO, Z. X.; tian, x. j.; ZHANG, R.; qiao, y.; Hua, d. x.; Zhang rui,Ma shiyang,

2020-05-29 molecular biology
10.1101/2020.05.29.123091 bioRxiv
Show abstract

BackgroundTo explore the potential therapeutic target to treat pancreatic cancers, Tspan1 was detected in human pancreatic cancer tissue and human pancreatic ductal adenocarcinoma cells and functional role of Tspan1 on proliferation was explored and the mechanism was investigated. Materials and MethodsTspan1 in PCC tissue and PDAC cell lines was measured by qRT-PCR and Western blot. Tspan1 was knock-downed and over-expressed in cells via transfection with Tspan1-siRNA and pLNCX-TSPAN1-cDNA, cell survival, proliferation and cell cycle were measured with MTT, Alamar blue and Flow Cytometry assay. The mRNA and protein expression were assessed by qRT-PCR and Western blotting. The expression of PI3K, Akt and p-Akt were detected, and CDK1 siRNA and specific inhibitor of Akt were used to explore the mechanism of TSPAN1 promoting PDAC cells proliferation. ResultsTspan1 expression in PCC tissue and PDAC cells was increased. Transfection of siRNA targeting Tspan1 in BxPC3 and PNAC-1 cells obviously decreased cell proliferation and down-regulated CDK1 expression. Consistently, both cell proliferation and CDK1 expression in BxPC3 and PNAC-1 cells were up-regulated with pLNCX-TSPAN1-cDNA transfection. Cell cycle analysis showed that after knockdown of Tspan1 the G2/M phase ratio was increased to cause mitosis arrest, and TSPAN1 overexpression caused cell cycle transition from G2 to M phase to promote cell proliferation. And these were dependent on the modulation of CDK1 expression via Akt. ConclusionTspan1 up-regulates CDK1 expression via activating Akt to promote human PCC cell proliferation and silencing of Tspan1 may be a potential therapeutic target to treat pancreatic cancers.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
Annals of Translational Medicine
17 papers in training set
Top 0.1%
23.1%
2
PLOS ONE
4510 papers in training set
Top 8%
19.1%
3
PeerJ
261 papers in training set
Top 2%
4.1%
4
Bioscience Reports
25 papers in training set
Top 0.2%
3.7%
5
Scientific Reports
3102 papers in training set
Top 34%
3.7%
50% of probability mass above
6
BMC Cancer
52 papers in training set
Top 0.8%
2.8%
7
Journal of Cellular and Molecular Medicine
18 papers in training set
Top 0.2%
1.9%
8
Frontiers in Medicine
113 papers in training set
Top 3%
1.9%
9
Frontiers in Oncology
95 papers in training set
Top 2%
1.8%
10
Molecular Biology Reports
19 papers in training set
Top 0.2%
1.5%
11
Medicine
30 papers in training set
Top 1%
1.4%
12
Heliyon
146 papers in training set
Top 3%
1.3%
13
Acta Biochimica et Biophysica Sinica
19 papers in training set
Top 0.5%
1.1%
14
Cell Death & Disease
126 papers in training set
Top 2%
1.1%
15
Informatics in Medicine Unlocked
21 papers in training set
Top 0.7%
1.1%
16
Virologica Sinica
10 papers in training set
Top 0.3%
1.0%
17
Diagnostics
48 papers in training set
Top 2%
1.0%
18
Frontiers in Pharmacology
100 papers in training set
Top 3%
1.0%
19
BMJ Open Diabetes Research & Care
15 papers in training set
Top 0.8%
0.9%
20
FEBS Open Bio
29 papers in training set
Top 0.4%
0.9%
21
Cells
232 papers in training set
Top 5%
0.9%
22
ACS Omega
90 papers in training set
Top 3%
0.8%
23
Cell Cycle
14 papers in training set
Top 0.4%
0.8%
24
Genomics
60 papers in training set
Top 3%
0.7%
25
International Journal of Biological Macromolecules
65 papers in training set
Top 4%
0.7%
26
Biochemistry and Biophysics Reports
28 papers in training set
Top 2%
0.7%
27
Bioengineering
24 papers in training set
Top 2%
0.7%
28
Frontiers in Immunology
586 papers in training set
Top 9%
0.7%
29
Journal of Personalized Medicine
28 papers in training set
Top 2%
0.5%
30
Biology Open
130 papers in training set
Top 4%
0.5%